Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
Biogena Group Invest AG's revenue for the
six
months ended in Jan. 2026 was €0.35 Mil.
Its revenue for the trailing twelve months (TTM) ended in Jan. 2026 was €0.35 Mil.
Biogena Group Invest AG's Revenue per Share for the
six
months ended in Jan. 2026 was €0.09.
Its Revenue per Share for the trailing twelve months (TTM) ended in Jan. 2026 was €0.09.
Warning Sign:
Biogena Group Invest AG revenue per share has been in decline for the last 5 years.
During the past 7 years, Biogena Group Invest AG's highest 3-Year average Revenue per Share Growth Rate was 11.80% per year. The lowest was -36.60% per year. And the median was 3.50% per year.
His favorite companies are stalwart, those growing between 10-20% a year.
Companies in cyclical industries may see their revenue fluctuate wildly in good years and bad years.
Be Aware
Revenue can be manipulated by changing the way how revenue is booked. Companies may book sales before the payment is received, or before the revenue is fully earned. These will be added to balance sheet items such as account payable or account receivables.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
For the Packaged Foods subindustry, Biogena Group Invest AG's Revenue, along with its competitors' market caps and Revenue data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Biogena Group Invest AG Revenue vs Consumer Packaged Goods Industry
For the Consumer Packaged Goods industry and Consumer Defensive sector, Biogena Group Invest AG's Revenue distribution charts can be found below:
* The bar in red indicates where Biogena Group Invest AG's Revenue falls into.
Also referred as sales, revenue is income that a company receives from its normal business activities, usually from the sale of goods and services to customers. Revenue is often referred to as the "top line" due to its position on the income statement at the very top.
For stock reported annually, GuruFocus uses latest annual data as the TTM data. Revenue for the trailing twelve months (TTM) ended in Jan. 2026 was €0.35 Mil.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Biogena Group Invest AG (WBO:BIO) has a Revenue of €0.35 Mil as of Jan. 2026. Revenue is the total amount a company generates as sales through its operations. View historical data on Biogena Group Invest AG and its competitors.
Is Biogena Group Invest AG's Revenue too high?
Biogena Group Invest AG's current Revenue is €0.35 Mil. Overall, Biogena Group Invest AG has a GF Score™ of 62/100 and is considered Significantly Overvalued, reflecting its overall financial health beyond just this single metric.
How does Biogena Group Invest AG's Revenue compare to KHC and GIS?
Biogena Group Invest AG's Revenue of €0.35 Mil can be compared against companies in the Consumer Packaged Goods industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Revenue for a Consumer Packaged Goods company?
A good Revenue depends on the Consumer Packaged Goods industry context. However, Revenue should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Revenue mean?
A high Revenue can signal that a stock is expensive relative to its fundamentals. Revenue is the total amount a company generates as sales through its operations. View historical data on Biogena Group Invest AG and its competitors. Biogena Group Invest AG's current Revenue is €0.35 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Biogena Group Invest AG stock overvalued right now?
Based on GuruFocus' analysis, Biogena Group Invest AG (WBO:BIO) is currently considered Significantly Overvalued. The stock's GF Value™ is €3.53, compared to a current price of €5.30 — trading 50.1% above its estimated fair value. The current Revenue is €0.35 Mil. Biogena Group Invest AG's overall GF Score™ is 62/100 with 7 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Revenue calculated?
Revenue is calculated from a company's financial statements. For Biogena Group Invest AG (WBO:BIO), the current Revenue is €0.35 Mil as of Jan. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Biogena Group Invest AG (WBO:BIO) Overvalued in 2026?
Based on GuruFocus' analysis, Biogena Group Invest AG stock appears to be overvalued.
The current stock price of €5.30 is trading 50.1% above its estimated GF Value™ of €3.53.
GuruFocus considers Biogena Group Invest AG to be Significantly Overvalued.
Key valuation signals for WBO:BIO:
Revenue: €0.35 Mil
GF Value™: €3.53 vs. price of €5.30 (50.1% above fair value)
No single metric tells the full story. See the WBO:BIO stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Biogena Group Invest AG is a holding company. It is engaged in the development and distribution of products and services in the field of health and nutrition. In particular, the focus is on iron, mineral and osteoporosis product innovations and new integrated solutions in the area of workplace health promotion. Its products include vitamin, mineral, enzymes, medicinal mushrooms, among others.
62GF Score
Get the complete analysis for WBO:BIO
Revenue is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
WBO:BIO has been successfully added to your 
